BEAT icon

Heartbeam

1.62 USD
-0.04
2.41%
At close Apr 17, 4:00 PM EDT
1 day
-2.41%
5 days
-1.82%
1 month
-23.22%
3 months
-24.30%
6 months
-27.03%
Year to date
-31.06%
1 year
-25.00%
5 years
-96.33%
10 years
-81.42%
 

About: HeartBeam Inc is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.

Employees: 21

0
Funds holding %
of 7,407 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

350% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 2

67% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 3

6% more funds holding

Funds holding: 32 [Q3] → 34 (+2) [Q4]

1% more capital invested

Capital invested by funds: $6.05M [Q3] → $6.12M (+$66.8K) [Q4]

0.14% more ownership

Funds ownership: 9.83% [Q3] → 9.97% (+0.14%) [Q4]

Research analyst outlook

We haven’t received any recent analyst ratings for BEAT.

Financial journalist opinion

Neutral
Seeking Alpha
1 month ago
HeartBeam, Inc. (BEAT) Q4 2024 Earnings Call Transcript
HeartBeam, Inc. (NASDAQ:BEAT ) Q4 2024 Results Conference Call March 13, 2025 4:30 PM ET Company Participants Rob Eno - Chief Executive Officer Tim Cruickshank - Chief Financial Officer Operator Greetings, and welcome to the HeartBeam Fourth Quarter and Full Year 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
HeartBeam, Inc. (BEAT) Q4 2024 Earnings Call Transcript
Neutral
Business Wire
1 month ago
HeartBeam Reports Fourth Quarter and Full Year 2024 Results
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Reports Fourth Quarter and Full Year 2024 Results.
HeartBeam Reports Fourth Quarter and Full Year 2024 Results
Neutral
Business Wire
1 month ago
HeartBeam to Participate at Upcoming Conferences in Dana Point, California, March 16-21, 2025
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam to Participate at Upcoming Conferences in Dana Point, California, March 17-21, 2025.
HeartBeam to Participate at Upcoming Conferences in Dana Point, California, March 16-21, 2025
Neutral
Business Wire
1 month ago
HeartBeam to Host Fourth Quarter Full Year 2024 Results Conference Call on Thursday, March 13, 2025 at 4:30 p.m. Eastern Time
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam to Host Fourth Quarter Full Year 2024 Results Conference Call on Thursday, March 13, 2025 at 4:30 p.m. Eastern Time.
HeartBeam to Host Fourth Quarter Full Year 2024 Results Conference Call on Thursday, March 13, 2025 at 4:30 p.m. Eastern Time
Neutral
Business Wire
1 month ago
HeartBeam Announces Exercise and Closing of Underwriter's Over-Allotment Option for Public Offering of Common Stock
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Announces Exercise and Closing of Underwriter's Over-Allotment Option for Public Offering of Common Stock.
HeartBeam Announces Exercise and Closing of Underwriter's Over-Allotment Option for Public Offering of Common Stock
Neutral
Business Wire
2 months ago
HeartBeam Announces Pricing of $10.0 Million Underwritten Public Offering of Common Stock
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Announces Pricing of $10.0 Million Underwritten Public Offering of Common Stock.
HeartBeam Announces Pricing of $10.0 Million Underwritten Public Offering of Common Stock
Neutral
Business Wire
2 months ago
HeartBeam Achieves Major Milestone with FDA Submission for its Groundbreaking 12-Lead ECG Synthesis Software
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Achieves Major Milestone with FDA Submission for its Groundbreaking 12-Lead ECG Synthesis Software.
HeartBeam Achieves Major Milestone with FDA Submission for its Groundbreaking 12-Lead ECG Synthesis Software
Neutral
Business Wire
3 months ago
HeartBeam to Attend JP Morgan 2025 Annual Healthcare Conference
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam to Attend JP Morgan 2025 Annual Healthcare Conference.
HeartBeam to Attend JP Morgan 2025 Annual Healthcare Conference
Neutral
Business Wire
4 months ago
HeartBeam Announces FDA Clearance for At-Home, High-Fidelity Heart Monitoring Technology
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Announces FDA Clearance for At-Home, High-Fidelity Heart Monitoring Technology.
HeartBeam Announces FDA Clearance for At-Home, High-Fidelity Heart Monitoring Technology
Neutral
Business Wire
4 months ago
HeartBeam Announces Positive Data from Two Studies at Prestigious American Heart Association Conference
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Announces Positive Data from Two Studies at Prestigious American Heart Association Conference.
HeartBeam Announces Positive Data from Two Studies at Prestigious American Heart Association Conference
Charts implemented using Lightweight Charts™